The AI Era of Protein Engineering: How to Achieve Efficient Industrial Application

1. Protein Modification: The 'Chip-Level' Technology of the Bio Industry

Proteins are the executors of life functions and the core components of modern bio-industries such as industrial enzymes, biopharmaceuticals, biosensors, and green catalysts. However, natural proteins are not entirely designed for industrial or clinical applications: many industrial enzymes work very well under standard lab conditions, but when exposed to harsh industrial environments like high temperature, high salinity, or organic solvents, they often struggle to remain stable and can easily lose activity. Therapeutic antibodies, while having strong targeting recognition, can aggregate or degrade during production and storage, affecting the actual effectiveness of the drug.

The core goal of "protein modification" technology is to enhance industrial and medical properties such as thermal stability, catalytic efficiency, substrate specificity, and expressibility, while retaining the protein’s original core functions.

Protein engineering uses methods like directed evolution, semi-rational design, and computer-aided rational design to optimize natural proteins. On top of that, de novo protein design can create entirely new proteins that don’t exist in nature. Engineered proteins after modification show high application value in several key areas:

- Biopharmaceuticals: Improve the stability of therapeutic enzymes and antibodies, reduce immunogenicity, and greatly increase drug development potential and druggability.

- Industrial catalysis: Engineered enzymes can serve as green catalysts for the synthesis of chemical raw materials and intermediates, helping the pharmaceutical industry achieve green and low-carbon manufacturing.

- Diagnostics and sensing: Modified diagnostic enzymes can significantly improve the accuracy and sensitivity of biological detection.

It’s clear that more stable, efficient, and smarter engineered proteins are reshaping the entire industry ecosystem, from new drug development to industrial green manufacturing.

2. Three Major Bottlenecks of Traditional Protein Engineering

Bottlenecks of Traditional Protein Engineering

Since protein engineering is crucial for the development of the biotech industry, why do most companies that need R&D find it so hard to effectively implement this core technology?

Traditional protein engineering has long followed an iterative R&D model of 'random mutation and functional screening,' with a very fixed core process: introduce gene mutations manually through error-prone PCR or site-saturation mutagenesis techniques to build libraries containing tens of thousands of mutants; use high-throughput screening technologies to pick out a small number of mutants with positive effects; then repeatedly carry out mutation and screening based on the high-quality mutants, typically needing 3 to 10 rounds of iteration to get a protein that meets the target requirements. This long-standing industry R&D path has three main core efficiency bottlenecks that are hard to overcome.

Bottleneck 1: The enormous combinatorial sequence space

Proteins are made up of 20 amino acids arranged in specific sequences, and the possible combinations of gene mutations are extremely huge. If you mutate 10 positions in a protein at the same time, the theoretical number of sequence combinations can reach 20¹⁰, about 10.24 trillion. Current lab high-throughput screening capabilities simply can't cover this astronomical combination space. Traditional directed evolution relies heavily on random sampling, blindly trying and testing in this vast sequence space, wasting a lot of screening effort on ineffective or harmful mutants. R&D resources get wasted, and overall efficiency is extremely low.

Bottleneck 2: “Epistatic Effect” Causes Mutation Combinations to Fail

The second bottleneck comes from the epistatic effect between mutation sites: this effect refers to the complex non-additive interactions between different mutations. It’s the 'hidden killer' that causes many protein engineering projects to stall mid-way and ultimately fail. In conventional R&D, through rational design or random mutagenesis, it’s usually possible to identify multiple single-point mutations that can individually improve enzyme thermal stability or catalytic activity. But when these high-quality single mutations are combined, complex interactions occur between mutation sites: some mutation effects cancel each other out, and some combinations may even completely inactivate the protein. These negative epistatic effects are a key reason for project failure. Restricted by this effect, companies mostly adopt a conservative 'introduce mutations one by one and verify in rounds' strategy, which directly leads to long development cycles and high human and financial costs.

Bottleneck 3: Limited Screening Throughput Buries the Potential of High-Quality Mutations

The iterative logic of traditional directed evolution has inherent flaws: each round of mutant library is built on the best variants from the previous round, and only a few top-performing variants are retained for the next iteration. The vast majority of mutant sequence data and functional information is discarded. This ‘chasing only the best, ignoring potential’ approach may miss a group of mutations that perform modestly in a single round but could have huge performance gains when combined, ultimately causing the best protein engineering solutions to be overlooked.

3.Paradigm Shift: AI is Redefining Protein Engineering Rules

The three core bottlenecks above essentially stem from the enormous protein sequence search space and the extremely complex interactions between mutation sites. Traditional optimization schemes can only rely on increasing screening rounds or expanding experimental throughput to improve success rates. At its core, it’s about using time, manpower, and money to fight the exponentially growing R&D complexity—treating the symptoms rather than the root problem. In the past two years, however, a series of cutting-edge research results have fundamentally broken this industry dilemma from the ground up and completely reshaped the traditional protein engineering R&D paradigm.

Breakthrough 1: MULTI-evolve — Single-round evolution achieves performance improvements by orders of magnitude

In 2026, an international research team published groundbreaking research in *Science*, introducing the novel MULTI-evolve protein engineering method. This approach leverages mature protein language models like ESM-2 to accurately screen for potentially beneficial single-point mutations, and then uses deep learning with neural networks to capture the synergistic effects between mutation sites, enabling the design of optimized multi-mutation combinations in one go. Multiple experimental results fully validate the incredible effectiveness of this technology:

- In APEX proximity labeling enzyme engineering, catalytic activity increased over 100-fold;

- In CRISPR-dCasRx (Cas13d variant) engineering, splicing activity improved by nearly 10 times at most;

- After obtaining basic data on single and double mutations, just one round of machine learning-guided wet experiments is enough to complete multi-mutation combination optimization.

This means that tasks which previously required 6 to 10 iterative rounds and took months or even years for directed evolution can now be completed in just a few weeks, achieving a qualitative leap in protein engineering efficiency.

Breakthrough 2: Domestic AI algorithm breakthrough — Accurate prediction of epistatic effects significantly increases design success

A local research team published an innovative study in *mLife*, proposing an AI-assisted enzyme thermal stability engineering strategy. Using a small amount of experimental data to fine-tune the ProPRIME protein language model, the team can accurately predict complex epistatic effects in combinatorial mutants, fundamentally solving the industry challenge of multi-mutation combination failure. In creatine kinase evolution experiments, this strategy showed extreme design precision and practical effectiveness:

- With only two rounds of design iteration, they successfully obtained 50 combinatorial mutants;

- The best mutant, 13M4, carries 13 mutation sites. Compared with the wild type, its activity remains almost unchanged, Tm increased by 10.19°C, and its half-life at 58°C increased by about 655 times, maintaining activity basically on par with the wild type.

Flowchart of the strategy

A series of cutting-edge scientific research achievements fully demonstrate that the protein modification industry is completely moving away from the traditional model of "relying on luck, manpower, and repeated trial and error," and is fully entering a new era of precision design driven by "prediction and data."

4. From Laboratory to Industry: The Implementation Paradigm of AI-Empowered Protein Transformation

Cutting-edge research in university laboratories has verified the technological limits of AI protein modification, but for biotech companies, what the industry truly lacks is a ready-to-use, low-barrier, and practical industrialization tool. Enterprises can efficiently complete high-precision protein modification R&D without building their own machine learning R&D teams, building large computing clusters, or developing their own high-throughput screening platforms.

To meet this core industry need, the MatwingsVenus™ (Xiaowu ™) intelligent agent conversational AI protein transformation platform was born, systematically optimizing and commercializing cutting-edge AI protein design technology in academia. Users only need to use simple dialogue and interaction to propose specific protein modification needs (such as "improving the thermal stability of target proteins, optimizing catalytic efficiency"), and the platform can automatically complete the entire intelligent operation process:

Relying on protein language models and professional sequence analysis algorithms, it intelligently generates multiple sets of high-quality multi-mutation combination modification plans;

Protocol evaluation is conducted from multiple dimensions such as protein folding risk, in vitro expressability, and functional stability, allowing users to independently select the best option;

Seamlessly integrates with automated shared laboratory systems, bridging the last mile from AI computing design to offline experimental validation, achieving a full-process closed-loop R&D.

For small and medium-sized enterprises and research institutions lacking high-end high-throughput screening equipment and professional bioinformatics R&D teams, the MatwingsVenus™ ™ intelligent system significantly lowers the entry barrier for protein modification industries. Enterprises do not need to invest millions in building dedicated screening platforms or hire high-paid dedicated R&D personnel, yet they can obtain professional mutation design solutions comparable to cutting-edge academic research.

MatwingsVenus™

5. The New Normal of Protein Transformation: AI Protein Engineering Becomes an Industry Standard

With the continuous iteration and upgrade of protein language models such as ESM2 and ProPRIME, combined with the popularization and maturity of automated experimental platforms, the fully closed-loop R&D model of "design, build, test, and learn" has evolved from mere academic research exploration to fully implemented industrial applications, with the industry as a whole showing three core development trends.

Trend 1: R&D models are shifting from random trial and error to prediction-driven approaches

Traditional directional evolution relies on repeated "mutation screening" cycles, resulting in lengthy R&D cycles and high trial-and-error costs. AI-assisted protein modification technology can quickly predict and sequence the adaptability of massive combination mutation sequences in a virtual environment, putting only the optimal candidate libraries into offline experimental validation, greatly reducing screening workload and comprehensively improving the efficiency and precision of protein evolution R&D development.

Trend 2: Optimization logic moves from single mutant iteration to multi-mutation collaboration

Top-tier effects were once industry pain points and technical barriers restricting multi-mutation combination transformation. Traditional R&D can only avoid risks by introducing single mutations step by step, which not only lengthens R&D cycles but also gradually diminishes performance improvements and keeps declining marginal returns. With the implementation of core technologies such as MULTI-evolve and ProPRIME, AI can accurately learn the synergistic patterns of higher-order mutants, achieving multi-mutation combinations >The combined efficiency boost of 2" greatly breaks through the performance bottlenecks of traditional technology.

Trend 3: AI empowerment accelerates the implementation of full-industry scenarios

Relying on AI precision transformation technology, the industrial application boundaries of protein engineering continue to expand, and the speed of implementation has accelerated comprehensively. In the biopharmaceutical field, high-quality modified proteins support the efficient development and iteration of therapeutic antibodies, enzyme therapies, and next-generation vaccines; In the field of industrial catalysis, high-performance engineered enzymes continue to replace traditional chemical catalysts, promoting the green and low-carbon transformation of the pharmaceutical synthesis industry; In vitro diagnostics, highly stable and highly sensitive modified enzymes provide core technical support for precision medical testing. As the threshold for using AI design tools continues to lower, the industrialization process across various fields will further accelerate.

Protein Engineering

Conclusion

Traditional protein engineering is essentially a massive trial-and-error process where only a few attempts succeed out of thousands. It consumes a huge amount of money, manpower, and time, and often faces risks like slow research progress and highly uncertain outcomes. From the MULTI-evolve technology published in *Science* to domestically developed AI-guided combinatorial mutation prediction models, multiple groundbreaking research achievements confirm that AI-driven protein engineering has completely moved beyond the proof-of-concept stage in labs and entered a new phase of scalable, industrial implementation.

Industrial tool platforms, represented by the MatwingsVenus™ (Xiaowu™) AI system, bring cutting-edge AI protein design capabilities from academia to the market, helping companies and research teams overcome high-tech barriers. This allows protein engineering to fully say goodbye to ‘blind luck-based trial and error’ and step into a new stage of ‘precision research powered by computing.’ For teams stuck in traditional trial-and-error methods with slow R&D progress, embracing the AI paradigm shift and switching to intelligent R&D tools is clearly the optimal choice to break technical bottlenecks and achieve higher efficiency and quality.